RxDoctor Payments Data

Jason Freeman, MD

Cardiology · Oceanside, NYNPI 1538244843

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Boston Scientific at 35.3% of the total. Reporting peaked in 2024 at $445 and has fallen 77.2% since, to $101 in 2025.

$1,393in general payments, 2019–2025

Across 60 payments — averaging $23.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$491
  • Abbott$211
  • Novartis$181
  • Pfizer$133
  • Kestra Medical Technology Services, Inc.$118
  • E.r. Squibb & Sons, L.L.C.$111
  • plus $148 from 4 others

What the payments were for

  • Food & beverage$1,393100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,393 in reported general payments places this provider in the 60th percentile of 112 cardiology providers in New York.

See all cardiology providers in New York

Medicare billing

Part B allowed, 2024
$129,063
Medicare patients
267
Services billed
949

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban53$61,469
BrilintaTicagrelor57$57,264
XareltoRivaroxaban18$28,839
Metoprolol Succinate191$3,456
ClopidogrelClopidogrel Bisulfate141$2,129
Atorvastatin Calcium209$2,126
Metoprolol Tartrate135$1,390
Simvastatin75$1,023
Amlodipine Besylate120$921
Ramipril34$829
Ezetimibe26$793
Prasugrel Hcl15$727
Rosuvastatin Calcium52$668
Lisinopril62$654
Telmisartan11$311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$133$61,46953 claims
Johnson & JohnsonXarelto$25$28,83918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 112 cardiology providers in New York.

Other cardiology in Oceanside

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →